https://t.co/sXtubCe8Ox
How might #bNAbs induce HIV remission?
Timothy Tipoe, @SarahFidler7@JohnFrater5 discuss the possible 'vaccinal' effect seen in people receiving bNAbs in this review.
The brilliant and indefatigable Ming Lee @jnim87 telling participants about his study in @RIOtrial taking gut biopsies to study the HIV reservoir- thanks to all the amazing people who take part in this study, which is one of the first in the world to do this!
The @RIOtrial is one of the very first testing amazing new ‘broadly neutralising antibody therapy’ in people living with HIV. Thank you to our amazing participants who give up so much time, dedication and blood samples!! Research would be impossible without you.
Professor Sarah Fidler talking about curing HIV to our amazing participants in the RIO trial- thank you to everyone taking part and your amazing dedication to the study @RIOtrial
@MarissaRothkopf . Thank you so much for inviting me onto your brilliant podcast to chat about both baking and viruses! I mean, really? Only you could pull this off with such effortless panache! https://t.co/UYSyN9rq4r
Well done to @PennyZach1 and all the Medawar team @NDMOxford. Your paper is out today: Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological… https://t.co/IZymF6Qn5O
Are you (or do you know) an ace post-doc looking for an exciting new job in T cells and TCR analysis? Come and join this exciting project based in Oxford as part of an amazing new international HIV Cure consortium. Check it out! @NDMOxford#hivcure
https://t.co/onmC7yZX3L
Exciting to see this fantastic collaboration led by Brad Jones and Marina Caskey up and running. Vital to keep the cure for HIV on the research agenda.
Here we go! Excited and humbled to be funded as a Martin Delaney collaboratory - the flagship @NIH program focusing on curing #HIV. Our program starts on Monday. We are ready to make an impact.
Leading by example.
#RIOtrial Chief investigator @sarahfidler4 volunteers to have bloods taken by the excellent @ImperialCRF staff during a training session. These larger research blood draws are undertaken by our participants at 3-monthly intervals.
Our paper - the first - involving CHERUB Investigators working with the Oxford Vaccine Group on safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine in people with HIV is out in Lancet HIV https://t.co/MF5yS7fU3l @NDMOxford
Research Assistant in Single Cell BCR and TCR Sequencing at University of Oxford https://t.co/278S6P4ViN Exciting job opportunity to join the CHERUB team. Looking for enthusiastic researchers with experience in molecular biology - no experience in microfluidics needed!
Forty years ago today the world changed forever with the first reported cases of what we now know to be HIV.
Since then, more than 30million lives have been lost to the epidemic. We've come a long way in the fight against HIV and seen huge medical progress – but it's not over.
#HIV History 🕰 40 years ago today the CDC put out its first report on a cluster of PJP among men in LA
This was the first report of #AIDS defining illness
Since then immense progress has been made to improve health of #PLHIV but we have even more work to do!
#Fourth90#EndStigma
Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy https://t.co/We18s7UPLi
Well done to @GenevieveEMart1 and all the @ukcherub team for this important new paper on how well antiretroviral therapy restores immune function @NDMOxford
Following this morning's discussions on COVID-19 and HIV, a timely pre-print by @johnfrater5@NDMOxford now released.
No difference in humoral or cellular immune responses to the Oxford ChAdox1 Vaccine in PLWH or HIV-negative people.
https://t.co/CW9LfxQRx1
#VaccinesWork
9: HIV and AIDS https://t.co/Za8l3z9wb6 #NowPlaying
Great to have been part of this fantastic Podcast series from @UniofOxford and @wellcometrust on the history of pandemics, and this episode particularly - a really clear overview of the impact of HIV @NDMOxford@ukcherub